pegfilgrastim
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Neutropenia
Conditions
Neutropenia
Trial Timeline
Feb 1, 2002 → Jun 1, 2004
NCT ID
NCT00035594About pegfilgrastim
pegfilgrastim is a phase 3 stage product being developed by Amgen for Neutropenia. The current trial status is completed. This product is registered under clinical trial identifier NCT00035594. Target conditions include Neutropenia.
What happened to similar drugs?
8 of 17 similar drugs in Neutropenia were approved
Approved (8) Terminated (5) Active (7)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00117910 | Phase 3 | Completed |
| NCT00035594 | Phase 3 | Completed |
Competing Products
20 competing products in Neutropenia